產(chǎn)品編號 | BIO0947SM |
英文名稱 | Anti-BAFF & IL-17A Reference Antibody (Tibulizumab Biosimilar) |
中文名稱 | |
別 名 | TNFSF13B / BAFF / CD257 & IL-17 / IL-17A / CTLA-8; Tibulizumab |
抗體來源 | |
克隆類型 | Monoclonal |
克 隆 號 | |
交叉反應(yīng) | Human |
產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | 201.44 kDa |
檢測分子量 | |
性 狀 | Lyophilized |
亞 型 | IgG-ScFv |
純化方法 | Protein A |
緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
保存條件 | -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles. |
注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產(chǎn)品介紹 | |
產(chǎn)品圖片 |
Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Tibulizumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Tibulizumab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 3.81 nM.
Tibulizumab bound to IL-17a protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Tibulizumab bound to in hu-IL-17a-His, and the EC50 was 0.128 nM.
Tibulizumab bound to BAFF protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Tibulizumab bound hu-BAFF-Fc, and the EC50 was 0.081 nM.
The purity of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 92.06%, determined by SEC-HPLC.
Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
1、抗體溶解方法 | |
2、抗體修復(fù)方式 | |
3、常用試劑的配制 | |
4、免疫組化操作步驟 | |
5、免疫組化問題解答 | |
6、Western Blotting 操作步驟 | |
7、Western Blotting 問題解答 | |
8、關(guān)于肽鏈的設(shè)計 | |
9、多肽的溶解與保存 | |
10、酶標抗體效價測定程序 | |